On the other hand, poor prognosis reflects the fewer treatment options available for er−, pr−, and her2/neu-negative tumours and the intrinsic biology of this subtype, which exhibits a high rate of relapse if complete eradication is not achieved and a poor outcome once relapse occurs 7. This evidence concerns the gene PGR and neoplasm.